Matthew W. Foehr - 02 Jan 2026 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role: Director
Signature: /s/ Michael Morneau, as Attorney-in-Fact
Issuer symbol: VKTX
Transactions as of: 02 Jan 2026
Net transactions value: -$508,414
Form type: 4
Filing time: 05 Jan 2026, 20:25:28 UTC
Previous filing: 09 Dec 2025
Next filing: 17 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
FOEHR MATTHEW W	Director	C/O VIKING THERAPEUTICS, INC., 9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO	/s/ Michael Morneau, as Attorney-in-Fact	05 Jan 2026	0001237556

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VKTX	Common Stock, par value $0.00001 per share	Options Exercise	$53,280	+16,000	+12%	$3.33	148,036	02 Jan 2026	Direct
transaction	VKTX	Common Stock, par value $0.00001 per share	Sale	$561,694	-16,000	-11%	$35.11	132,036	02 Jan 2026	Direct	F1
transaction	VKTX	Common Stock, par value $0.00001 per share	Award	$0	+3,150	+2.4%	$0.000000	135,186	02 Jan 2026	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VKTX	Stock Option (Right to Buy)	Options Exercise	$0	-16,000	-100%	$0.000000	0	02 Jan 2026	Common Stock	16,000	$3.33	Direct
transaction	VKTX	Stock Option (Right to Buy)	Award	$0	+20,400		$0.000000	20,400	02 Jan 2026	Common Stock	20,400	$35.42	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.94 to $35.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2	Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award.

Content

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.94 to $35.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award.